iNtRON Biotechnology, Inc.

KOSDAQ 048530.KQ

iNtRON Biotechnology, Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 43.92 M

iNtRON Biotechnology, Inc. Cash and Short-Term Investments is USD 43.92 M for the year ending December 31, 2023, a -48.63% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

iNtRON Biotechnology, Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 85.49 M, a -10.00% change year over year.
iNtRON Biotechnology, Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 95.00 M, a 56.39% change year over year.
iNtRON Biotechnology, Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 60.74 M, a 1.29% change year over year.
iNtRON Biotechnology, Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 59.97 M, a 102.62% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

KOSDAQ: 048530.KQ

iNtRON Biotechnology, Inc.

CEO	Mr. Seong-Jun Yoon
IPO Date	Jan. 26, 2011
Location	South Korea
Headquarters	137, Sagimakgol-ro
Employees	76
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Vaccines

Description

iNtRON Biotechnology, Inc. develops biopharmaceuticals for the prevention and treatment of human diseases worldwide. It develops bacteriophage and endoricin drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.

Key trends

Past 5 years